Lamivudina E Zidovudina Aurobindo

Zidovudine and Lamivudine, the active ingredients in Lamivudina E Zidovudina, are nucleoside reverse transcriptase inhibitors presented as oral tablets for systemic use. They are employed in the management of HIV-1 infection in adults, adolescents, and children, helping to suppress viral replication and improve immune function.

GNH USA supplies Lamivudina E Zidovudina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality, regulatory compliance and timely global logistics, and comprehensive customer support.

Lamivudina E Zidovudina combines zidovudine and lamivudine, nucleoside reverse transcriptase inhibitors used in antiretroviral therapy for HIV infection. - HIV-1 infection (adults): reduces viral load and helps restore CD4+ T‑cell counts. - Prevention of mother‑to‑child transmission: lowers the risk of vertical HIV transmission when given to pregnant women. - Pediatric HIV infection: improves immune function and slows disease progression in children living with HIV.

Lamivudina E Zidovudina may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild stomach upset. - Headache: transient pain. - Fatigue: general tiredness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic disturbance. - Hepatic steatosis: fatty liver disease. - Bone marrow suppression: pancytopenia risk. - Severe hypersensitivity: rash, fever, organ involvement.

When prescribing Lamivudina E Zidovudina, clinicians should observe several precautionary measures to minimize risks. - Monitor blood counts: regular CBC to detect anemia or neutropenia. - Assess liver function: periodic LFTs for signs of hepatic toxicity. - Evaluate renal function: dose adjustments may be needed in renal impairment. - Counsel on pregnancy: discuss potential risks and alternative regimens. - Review concomitant medications: avoid known major drug interactions. - Store at ambient temperature: keep tablets in original container, protect from moisture and heat.

Lamivudina E Zidovudina can interact with other medicines, influencing efficacy or toxicity.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis and mitochondrial toxicity. - Stavudine: additive mitochondrial toxicity and lactic acidosis. - Protease inhibitors boosted with ritonavir: may raise zidovudine concentrations.

Moderate Interactions (Monitor Closely): - Other NRTIs (e.g., tenofovir): monitor for combined bone marrow suppression. - Non‑nucleoside reverse transcriptase inhibitors (e.g., efavirenz): may alter plasma levels. - Warfarin: possible INR changes, require regular monitoring.